Therapeutic antibodies are used mostly in oncology and auto-immune diseases, but they are not used yet in gynaecology and endocrinology, where the absence of suitable markers for reproductive aging in women is a growing problem as families start at later parental ages. Follicle-stimulating hormone (FSH) glycosylation is a predicator of fertility treatment success. GlycoFormA Ltd. developed an anti-FSH antibody specific of a deglycosylated FSH isoform. Mediante MAbTope, su herramienta informática de mapeado de epítopos, MAbSilico pudo caracterizar el anticuerpo GlycoFormA. Twist Bioscience technology was used to generate the FSH constructs which were used to validate the prediction in its wet-lab facility.